MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 881 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-3
<p>HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.</p>Fórmula:C23H22F4N6O2Forma y color:SolidPeso molecular:490.45SOS1-IN-9
<p>SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).</p>Fórmula:C22H28F3N5OForma y color:SolidPeso molecular:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Fórmula:C30H37FN10OSForma y color:SolidPeso molecular:604.745KRAS G12C inhibitor 44
<p>KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.</p>Fórmula:C31H36ClFN6O2Forma y color:SolidPeso molecular:579.11Rho GTPase inhibitor 1
CAS:<p>Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.</p>Fórmula:C18H16N2OForma y color:SolidPeso molecular:276.33MEK4 inhibitor-2
CAS:<p>MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.</p>Fórmula:C20H15FN4O3SForma y color:SolidPeso molecular:410.42EBI-907
CAS:<p>EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.</p>Fórmula:C23H21ClF2N4O3SForma y color:SolidPeso molecular:506.95Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Fórmula:C32H30ClFN6O4Pureza:98.04%Forma y color:SolidPeso molecular:617.07JD123
CAS:<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>Fórmula:C12H11N5S2Forma y color:SolidPeso molecular:289.379L 739749
CAS:<p>L 739749 is a CAAX peptidomimetic. It is also an inhibitor of farnesyl-protein transferase.</p>Fórmula:C24H41N3O6S2Pureza:98%Forma y color:SolidPeso molecular:531.73SOS1-IN-6
CAS:<p>SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).</p>Fórmula:C26H28F3N3O2Forma y color:SolidPeso molecular:471.51LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Fórmula:C24H30FN5O2Forma y color:SolidPeso molecular:439.53HPK1-IN-21
<p>HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.</p>Fórmula:C22H25ClFN5O2Forma y color:SolidPeso molecular:445.92MEK1/2-IN-2
<p>MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.</p>Fórmula:C28H22ClFN6OForma y color:SolidPeso molecular:512.97HPK1-IN-16
CAS:<p>HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.</p>Fórmula:C28H27FN4OForma y color:SolidPeso molecular:454.54Cot inhibitor-3
CAS:<p>Cot inhibitor-3 (Compound 33) is an effective and selective cancerosaka thyroid (COT) kinase inhibitor with an IC50 of 4 nM. It can be used to prevent limpness caused by inflammation.</p>Fórmula:C30H28N8OForma y color:SolidPeso molecular:516.60HPK1-IN-31
<p>HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .</p>Fórmula:C30H33N7O3Forma y color:SolidPeso molecular:539.63AMG-548 dihydrochloride
<p>AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.</p>Fórmula:C29H29Cl2N5OForma y color:SolidPeso molecular:534.48BMS-214662
CAS:BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.Fórmula:C25H23N5O2S2Pureza:99.58% - 99.58%Forma y color:SolidPeso molecular:489.61ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Fórmula:C36H34FN7O2SPureza:98%Forma y color:SolidPeso molecular:647.76
